Boehringer Ingelheim and New York-based Immunai announced a multi-project discovery collaboration valued at up to USD 15 million, extending through 2027, focused on identifying novel T-cell targets across immuno-oncology and autoimmune disease. The collaboration will apply Immunai’s single-cell AI platform to datasets spanning both oncology and autoimmune disease, with Boehringer using the resulting insights to support future drug discovery programs. The two companies noted explicit expansion potential based on scientific progress and mutual agreement.
Immunai contributes its AMICA-OS AI operating system, which integrates harmonized single-cell multi-omic data with foundation AI models and lab-based functional validation. Under the initial program, the companies will build a shared data foundation spanning cancer and autoimmune disease samples, apply the platform across thousands of patient specimens to map T-cell dysfunction patterns, and conduct wet lab validation of the most promising findings. Boehringer Ingelheim contributes funding and its drug discovery infrastructure, assuming responsibility for advancing any resulting programs into its development pipeline. No specific drug candidates are named; the collaboration operates entirely at the target identification and hypothesis generation stage.
The Boehringer Ingelheim-Immunai collaboration adds to a pattern of pharma investment in Immunai’s AMICA-OS platform that has accelerated over the past 18 months. In January 2026, Immunai announced a collaboration with Bristol Myers Squibb to apply the platform across oncology clinical development programs. In May 2026, Immunai disclosed a third expansion of its multi-year collaboration with AstraZeneca, with Immunai eligible to receive up to USD 37.5 million under that arrangement. The AstraZeneca relationship originated in September 2024 with an initial USD 18 million phase. The Boehringer Ingelheim deal extends Immunai’s pharma partner roster to at least three top-10 companies within roughly 18 months, each structured around translating high-dimensional immune data into actionable drug discovery insights. For Boehringer Ingelheim, the transaction fits a broader pattern of AI-driven target discovery partnerships signed in 2025 and 2026, including a deal with Seattle-based Variant Bio for kidney disease targets worth potentially over USD 120 million, and a collaboration with 3T Biosciences covering T-cell receptor antigen discovery in oncology.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/